Xynomic Pharmaceuticals Inc., of Cheyenne, Wyo., said it acquired exclusive worldwide rights to develop, manufacture and commercialize abexinostat, which the company describes as a potentially best-in-class HDAC inhibitor targeting hematological and solid tumors.